Clinuvel Pharmaceuticals

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Weighted Moving Average

Score

-0.45

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 14 34.5 0.50% 1.00% 26.5% -6.3% 141.3%
SHORT 15 15.9 0.13% 0.15% 4.2% -6.1% -71.2%

Summary

Technical Analysis

Clinuvel Pharmaceuticals (CUV.AX)


Indicator:

WEIGHTED MOVING AVERAGE


Last Signal:

BEARISH


Trading: SELL @ $25.03
Signal Strength: STRONG
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.


Clinuvel Pharmaceuticals (ASX:CUV) currently has a confirmed downtrend. Recent trading has caused the WMA 15 day average to move below the closing price confirming the short term trend following indicator. Currently, the return on WMA15 is -2.6%.



Weighted moving averages (WMA) are difficult to construct but more reliable than the simple moving averages. WMA permits an unequal weighting on prior time periods.

Calculation: Weighted Moving Average (WMA):
1) Ft= W1At-1 + WnAt-n


PROFILE: Clinuvel Pharmaceuticals (CUV.AX)


Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |

About Clinuvel Pharmaceuticals (ASX:CUV):

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.

Top 10:

Weighted Moving Average

Download
Company Close Change(%) Volume Value Signal
BBN Baby Bunting 2.7 11.1 2,595,338 0.6 BULLISH
NBL Noni B 2.58 5.3 52,656 0.1 BULLISH
AHG Advance Healthcare 3.21 4.6 663,989 6.7 BULLISH
CAJ Capitol Health 0.23 4.5 159,441 5.8 BULLISH
GSW Getswift 0.25 4.2 499,320 3.4 BULLISH
SHM Shriro 0.67 3.9 91,198 3 BULLISH
CAT Catuity 1.17 3.6 340,110 5.7 BULLISH
GMA Genworth Mortgage Insurance Australia 2.99 3.5 1,025,015 2.4 BULLISH
JHC Japara Healthcare 1.04 3.5 410,500 0.5 BULLISH
APZ Aspen 1.09 3.3 9,720 6.3 BULLISH